12.00
+0.78(+6.95%)
Currency In USD
| Previous Close | 11.22 |
| Open | 11.36 |
| Day High | 12.33 |
| Day Low | 11.4 |
| 52-Week High | 18.2 |
| 52-Week Low | 9.24 |
| Volume | 3.96M |
| Average Volume | 1.57M |
| Market Cap | 3.75B |
| PE | 0 |
| EPS | 0 |
| Moving Average 50 Days | 10.29 |
| Moving Average 200 Days | 10.64 |
| Change | 0.78 |
Data not available
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
GlobeNewswire Inc.
Dec 20, 2024 11:16 AM GMT
~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and young people (1 month-17 years of age) ~ ~ Data from
Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management
GlobeNewswire Inc.
Dec 19, 2024 11:13 AM GMT
~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million Shares ~ RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2024 (G
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
GlobeNewswire Inc.
Nov 13, 2024 11:27 AM GMT
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Crai